CAR-MA Preparation Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging. Given the unique effector functions of macrophages and their capacity to penetrate tumors, genetically engineered human macrophages with CARs make it possible to produce direct phagocytic activity against tumors. Creative Biolabs is pleased to announce our custom chimeric antigen receptor macrophage (CAR-MA) preparation service.

Fig.1 CAR-MA transfection approaches.
(Creative Biolabs)

Virus Packaging Service

Macrophages are highly resistant to genetic engineering with standard vectors such as lentivirus, retrovirus, and adeno-associated viruses (AAV). The vector requires fine-tuning and molecular adjustments to better transfer to macrophages.

Lentiviral vector: Vpx, an accessory protein, can bind to and counteract lentivirus restriction factor SAMHD1. The use of Vpx-packaged lentiviral particles for transduction of myeloid cells will lead to a restored level of dNTPs, which indicates successful reverse transcription of the lentiviral vector constructs.
Ad5F35 vector: Macrophages are efficiently transduced by the chimeric-fiber adenoviral vector Ad5F35. Importantly, the transduction with Ad5F35 vector-regardless of CAR expression induces a pro-inflammatory M1 phenotype in the infected macrophages with upregulation of interferon-induced and antigen-presenting machinery genes. Ad5f35 transduced primary human CAR-MA has demonstrated targeted phagocytosis.

CAR-MA Generation

Creative Biolabs provides reliable and available sources of macrophages including induced pluripotent stem cells (iPSC), human monocytic cell line (THP-1), human primary macrophages (CD14+ peripheral blood), murine macrophages (Raw264.7, J774A.1), etc. In general, iPSC-derived macrophages may become an important source of cells for myeloid-based cancer immunotherapy.

Macrophages derived from different sources can be genetically altered with CAR constructs. Fig.2 Macrophages derived from different sources can be genetically altered with CAR constructs. (Abdin, 2021)

With an experienced expert team, Creative Biolabs offers high-quality CAR-MA preparation services. If you are interested in our services, please feel free to contact us.

Reference

Abdin, S.M.; et al. CARs and beyond: tailoring macrophage based cell therapeutics to combat solid malignancies. Journal for Immuno Therapy of Cancer. 2021, 9:e002741.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION